ArticleDiscover oncology2026
Bibliometric analysis of research trends and collaboration patterns in cardio-oncology focusing on lung cancer and heart failure.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).Human vaccines & immunotherapeutics · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer (LC) and heart failure (HF) are being increasingly seen as related conditions, with rising concerns about the cardiotoxic effects of treatments.
methodsWe conducted a bibliometric study on research related to LC and HF from 2014 to 2024 using the Web of Science Core Collection. To examine research trends and collaborations, data were analyzed and visualized using R, CiteSpace, and VOSviewer.
resultsThe research encompassed 531 articles from 194 different journals, with contributions from 3963 authors. The United States and China have been the leading contributors to LC and HF research, with 146 and 120 publications, and 5307 and 1403 citations, respectively. Carmen Bergom from the United States, along with Aidan J. Cole, Suneil Jain, and Gerard M. Walls from the United Kingdom, are recognized leaders in this field due to their prolific publications. Lancet Oncology has consistently and significantly impacted the field, and an article in the Journal of Clinical Oncology, which is the most cited, examines cardiac toxicity after radiotherapy for Stage III non-small-cell lung cancer through a pooled analysis of dose-escalation trials delivering 70 to 90 Gy. The focus of recent research is on immunotherapy (ICIs), cardiac toxicity associated with radiotherapy, and palliative care.
conclusionThis innovative mapping research highlights an increasing focus on the link between LC and HF, particularly concerning treatment-induced cardiotoxicity. Nonetheless, studies on their two-way interaction are still scarce, pointing to a promising yet under-researched area. Combining oncology and cardiology could reveal new insights to tailor personalized care and enhance results. Our research provides a foundation for future interdisciplinary investigations in the developing field of cardio-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.